Form 4: Rigel Pharmaceuticals CFO Reports Stock Transaction
Insider Transaction (Form 4)
Dean L Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals Inc, reported multiple transactions in common stock on September 1, 2026.
Summary
- Tax/exercise-price withholding: disposed of 928 Common Stock at $47.50 ($44,080) on September 1, 2026; holds 78,362 after (Direct).
- Option exercise/conversion: acquired 694 Common Stock at $12.70 ($8,814) on September 2, 2026; holds 79,056 after (Direct).
- Option exercise/conversion: acquired 620 Common Stock at $18.70 ($11,594) on September 2, 2026; holds 79,676 after (Direct).
- Option exercise/conversion: acquired 2,000 Common Stock at $24.20 ($48,400) on September 2, 2026; holds 81,676 after (Direct).
- Option exercise/conversion: acquired 1,286 Common Stock at $24.20 ($31,121) on September 2, 2026; holds 82,962 after (Direct).
- Option exercise/conversion: disposed of 694 Employee Stock Option (right to buy) on September 2, 2026; holds 12,824 after (Direct).
- Option exercise/conversion: disposed of 620 Employee Stock Option (right to buy) on September 2, 2026; holds 9,012 after (Direct).
- Option exercise/conversion: disposed of 2,000 Employee Stock Option (right to buy) on September 2, 2026; holds 7,999 after (Direct).
- Option exercise/conversion: disposed of 1,286 Employee Stock Option (right to buy) on September 2, 2026; holds 15,867 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Dean L Schorno — Officer (EVP & Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Tax/exercise-price withholding | Common Stock | 928 | $48 | $44.1K | 78,362 |
| 2026-09-02 | Option exercise/conversion | Common Stock | 694 | $13 | $8.8K | 79,056 |
| 2026-09-02 | Option exercise/conversion | Common Stock | 620 | $19 | $11.6K | 79,676 |
| 2026-09-02 | Option exercise/conversion | Common Stock | 2,000 | $24 | $48.4K | 81,676 |
| 2026-09-02 | Option exercise/conversion | Common Stock | 1,286 | $24 | $31.1K | 82,962 |
| 2026-09-02 | Option exercise/conversion | Employee Stock Option (right to buy) | 694 | — | — | 12,824 |
| 2026-09-02 | Option exercise/conversion | Employee Stock Option (right to buy) | 620 | — | — | 9,012 |
| 2026-09-02 | Option exercise/conversion | Employee Stock Option (right to buy) | 2,000 | — | — | 7,999 |
| 2026-09-02 | Option exercise/conversion | Employee Stock Option (right to buy) | 1,286 | — | — | 15,867 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Tax/exercise-price withholding (928 shares) |
| 2026-09-02 | Option exercise/conversion (694 shares) |
| 2026-09-02 | Option exercise/conversion (620 shares) |
| 2026-09-02 | Option exercise/conversion (2,000 shares) |
| 2026-09-02 | Option exercise/conversion (1,286 shares) |
| 2026-09-02 | Option exercise/conversion (694 shares) |
| 2026-09-02 | Option exercise/conversion (620 shares) |
| 2026-09-02 | Option exercise/conversion (2,000 shares) |
| 2026-09-02 | Option exercise/conversion (1,286 shares) |
Keywords
insider transaction, Form 4, RIGL, RIGEL PHARMACEUTICALS INC, neutral, Dean L Schorno
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.